600161 天坛生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,465,0729.62%6,031,8655,180,4424,261,3054,112,156
减:营业总成本3,110,81129.73%3,517,6813,429,7642,906,7942,873,225
    其中:营业成本2,508,78437.87%2,732,4402,550,7212,170,0242,157,687
               财务费用59-100.19%(32,914)(49,525)(57,989)(64,148)
               资产减值损失(7,483)375.69%(53,018)(2,167)(2,254)(15,146)
公允价值变动收益------------
投资收益25,893-17.02%63,92737,21328,12712,000
    其中:对联营企业和合营企业的投资收益------------
营业利润1,354,284-21.56%2,557,7851,804,9951,432,1151,244,907
利润总额1,347,397-21.86%2,547,2181,798,5981,426,2731,241,018
减:所得税费用226,940-23.60%434,953289,140221,598172,204
净利润1,120,457-21.50%2,112,2651,509,4591,204,6751,068,814
减:非控股权益301,771-19.67%563,100399,570323,758308,802
股东净利润818,686-22.16%1,549,1651,109,889880,916760,012

市场价值指针
每股收益 (元) *0.410-22.64%0.7800.5600.5300.470
每股派息 (元) *0.150--0.1000.1500.0500.100
每股净资产 (元) *5.7977.72%5.6335.9615.3405.864
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容